Literature DB >> 10364198

Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation.

S Gibson1, S Tu, R Oyer, S M Anderson, G L Johnson.   

Abstract

Chemotherapeutic drugs that damage DNA kill tumor cells, in part, by inducing the expression of a death receptor such as Fas or its ligand, FasL. Here, we demonstrate that epidermal growth factor (EGF) stimulation of T47D breast adenocarcinoma and embryonic kidney epithelial (HEK293) cells protects these cells from Fas-induced apoptosis. EGF stimulation of epithelial cells also inhibited Fas-induced caspase activation and the proteolysis of signaling proteins downstream of the EGF receptor, Cbl and Akt/protein kinase B (Akt). EGF stimulation of Akt kinase activity blocked Fas-induced apoptosis. Expression of activated Akt in MCF-7 breast adenocarcinoma cells was sufficient to block Fas-mediated apoptosis. Inhibition of EGF-stimulated extracellular signal-regulated kinase (ERK) activity did not affect EGF protection from Fas-mediated apoptosis. The findings indicate that EGF receptor stimulation of epithelial cells has a significant survival function against death receptor-induced apoptosis mediated by Akt.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364198     DOI: 10.1074/jbc.274.25.17612

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF.

Authors:  K H Limesand; K A Barzen; D O Quissell; S M Anderson
Journal:  Cell Death Differ       Date:  2003-03       Impact factor: 15.828

2.  Epithelial intestinal cell apoptosis induced by Helicobacter pylori depends on expression of the cag pathogenicity island phenotype.

Authors:  G Le'Negrate; V Ricci; V Hofman; B Mograbi; P Hofman; B Rossi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Authors:  Maxwell N Skor; Erin L Wonder; Masha Kocherginsky; Anju Goyal; Ben A Hall; Yi Cai; Suzanne D Conzen
Journal:  Clin Cancer Res       Date:  2013-09-09       Impact factor: 12.531

Review 4.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Authors:  Ami P Vaidya; Aric D Parnes; Michael V Seiden
Journal:  Curr Treat Options Oncol       Date:  2005-03

5.  EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.

Authors:  David E Gerber
Journal:  Drug Dev Res       Date:  2008-12-09       Impact factor: 4.360

6.  Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage.

Authors:  Jorge Berlanga; Pedro Prats; Diadelis Remirez; Ricardo Gonzalez; Pedro Lopez-Saura; Jorge Aguiar; Miriam Ojeda; Joseph J Boyle; Anthony J Fitzgerald; Raymond J Playford
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.

Authors:  Fabrizio Griffero; Antonio Daga; Daniela Marubbi; Maria Cristina Capra; Alice Melotti; Alessandra Pattarozzi; Monica Gatti; Adriana Bajetto; Carola Porcile; Federica Barbieri; Roberto E Favoni; Michele Lo Casto; Gianluigi Zona; Renato Spaziante; Tullio Florio; Giorgio Corte
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

8.  Caspase-1 mediates Fas-induced apoptosis and is up-regulated by interferon-gamma in human astrocytoma cells.

Authors:  Chulhee Choi; Eunjoo Jeong; Etty N Benveniste
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

10.  Norsolorinic acid from Aspergillus nidulans inhibits the proliferation of human breast adenocarcinoma MCF-7 cells via Fas-mediated pathway.

Authors:  Clay C C Wang; Yi-Ming Chiang; Po-Lin Kuo; Jiunn-Kae Chang; Ya-Ling Hsu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-03-16       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.